Zacks Investment Research
20 Aug 2026, 13:51 UTC · 1h ago
Is Cancer the Next Breakthrough for Moderna After COVID-19?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
20 Aug 2026, 13:51 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Moderna and Merck announced positive Phase III results for their personalized mRNA cancer therapy, intismeran autogene, in combination with Keytruda for high-risk melanoma. — Positive late-stage clinical trial results for a new therapeutic area provide critical validation for Moderna's post-COVID business model and market expansion.
+0.80The INTerpath-001 study met its primary endpoint of recurrence-free survival (RFS) and key secondary endpoint of distant metastasis-free survival (DMFS). — Meeting primary and secondary endpoints significantly increases the probability of regulatory approval and future commercialization.
+0.60Moderna and Merck intend to engage with regulators regarding potential filings based on these Phase III results. — This signals the transition from clinical testing to the formal regulatory approval process, bringing the product closer to market.
+0.40Continue reading
6 related stories
Top 3 movers · tap to explore
Moderna's shares rose 177% in a single day, adding over $44 billion to its market capitalization following the announcement. — While a massive price move, this is a market reaction to the news rather than a new fundamental driver, though it confirms strong investor appetite.
+0.20Which stocks this story touches
Shares soared 177% following positive phase III results for its personalized mRNA cancer therapy.
Positive phase III results for a cancer therapy developed in partnership with Moderna.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
5h ago
